SINOVAC Board Files Investor Presentation on Protecting Shareholder Interests

SINOVAC Board Takes Decisive Action to Restore Shareholder Value and Fairness

Shareholders Urged to Vote “AGAINST” Misguided Proposals to Replace the Board

Dedicated Website Launched: www.VoteSinovac.com

BEIJING – SINOVAC Biotech Ltd. (NASDAQ: SVA), a major player in China’s biopharmaceutical landscape, is making a bold move to safeguard shareholder interests. The company’s board of directors today announced the filing of an investor presentation with the U.S. Securities and Exchange Commission (SEC) and the launch of a dedicated website, www.VoteSinovac.com, ahead of its upcoming Special Meeting of Shareholders on July 9, 2025 (China Standard Time). The stakes are high, with the current board urging shareholders to reject proposals that could fundamentally alter the company’s direction.

The investor presentation lays out the current board’s commitment to revitalizing SINOVAC and maximizing shareholder value. It’s a counter-narrative to the claims of Advantech/Prime Success and Vivo Capital, collectively known as the “Dissenting Investor Group,” whose actions, according to the current board, have repeatedly put SINOVAC shareholders at a disadvantage.

Here’s a breakdown of the key points presented in the investor presentation:

• The current SINOVAC Board is highlighting its focus on dividend payments, having paid out up to US$138.73 per common share¹ in dividends in just four months since taking over. This stands in stark contrast to the previous board, which failed to issue any dividends over seven years.

• The board emphasizes its efforts to protect the rights of all common shareholders, including defending against lawsuits brought by the Dissenting Investor Group and ensuring that legitimate shareholders receive their rightful distributions.

• A strategic realignment is underway, aimed at undoing years of questionable practices, regaining compliance with NASDAQ listing standards (and resuming trading), and exploring a possible listing on the Hong Kong Stock Exchange. This move is intended to boost liquidity while executing on a global growth strategy. This is a key part of the plan to enhance shareholder value.

• The board is painting a picture of the Dissenting Investor Group, by contrast, as misleading and self-serving—pointing to failed privatization attempts at below market prices, self-dealing transactions, and efforts to block dividend payments. As an example, the current board points to the recent press release from Advantech/Prime. That release attempted to portray its defeat in a recent New York lawsuit as a victory—a claim quickly refuted in court.

Why Your Vote Matters

The central message from the current board? Your vote, due on or before July 8, is crucial. It will determine the near-term receipt of dividend payments, as well as the future value of the shareholders’ investment.

Shareholders are strongly advised to vote the WHITE proxy card “AGAINST” both Proposal 1, which seeks to remove the current board, and Proposal 2, which seeks to install the Reconstituted Imposter Board Slate. The company is clear: Discard any materials promoting the opposing slate. If you have already voted for them, you can change your vote using the WHITE proxy card.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company focused on the research and development, manufacturing, and commercialization of vaccines. The company’s broad portfolio includes vaccines targeting a range of infectious diseases.

SINOVAC’s CoronaVac® vaccine has been approved in over 60 countries. Additionally, its hepatitis A vaccine, Healive®, and EV71 vaccine, Inlive®, have achieved significant milestones.

The company has a long history of innovative vaccine development.

The market will be watching closely to see how this proxy fight plays out and what impact it will have on SINOVAC’s future.

Important Information for Shareholders

SINOVAC has filed a definitive proxy statement and other documents with the U.S. Securities and Exchange Commission (“SEC”). These documents, including the WHITE proxy card, are available at both the SEC’s website, www.sec.gov, and SINOVAC’s website: https://www.sinovac.com/en-us/Investors/sec_filings. Investors can also contact the Investor Relations Department at [email protected].

Safe Harbor

This announcement and any forward-looking statements are subject to risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623127700/en/